Corcept Therapeutics (CORT) Change in Accured Expenses (2010 - 2026)

Corcept Therapeutics has disclosed Change in Accured Expenses across 17 years of filings, most recently posting -$9.4 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$9.4 million, down 59.72% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.4 million (down 39.76% YoY), and the FY2025 annual result was $86000.0, down 99.31% from the prior year.
• Change in Accured Expenses came in at -$9.4 million for Q1 2026 at Corcept Therapeutics, up from -$17.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $17.2 million in Q3 2025 to a low of -$17.1 million in Q4 2025.
• The 5-year median for Change in Accured Expenses is $5.0 million (2022), against an average of $1.4 million.
• Across the five-year window, Change in Accured Expenses tumbled 401.45% in 2022 and soared 1261.22% in 2023, its largest moves.
• Corcept Therapeutics' Change in Accured Expenses stood at $802000.0 in 2022, then jumped by 1261.22% to $10.9 million in 2023, then plunged by 43.83% to $6.1 million in 2024, then slumped by 378.51% to -$17.1 million in 2025, then soared by 45.09% to -$9.4 million in 2026.
• The last three Change in Accured Expenses figures came in at -$9.4 million (Q1 2026), -$17.1 million (Q4 2025), and $17.2 million (Q3 2025), per Business Quant data.